Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours.
AuthorsPatterson, A V
Williams, Kaye J
Cowen, Rachel L
Telfer, Brian A
Saunders, Mark P
Van der Kogel, A J
Wolf, C R
Stratford, Ian J
AffiliationSchool of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractOverwhelming clinical and experimental data demonstrate that tumour hypoxia is associated with aggressive disease and poor treatment outcome as hypoxic cells are refractive to radiotherapy and some forms of chemotherapy. However, hypoxia is rare in physiologically normal tissues representing a tumour-specific condition. To selectively target this therapeutically refractive cell population, we have combined bioreductive chemotherapy with hypoxia-directed gene therapy. We have transfected the human fibrosarcoma cell line, HT1080, with a hypoxia-regulated expression vector encoding the human flavoprotein cytochrome c P450 reductase (HRE-P450R). This conferred hypoxia-dependent sensitivity to the alkylating nitroimidazole prodrug RSU1069 in vitro, with a greater than 30-fold increase in oxic/hypoxic cytotoxicity ratio compared with controls. Xenografts of both the HRE-P450R and empty vector transfectants had comparable hypoxic fractions and were refractive to single dose radiotherapy of up to 15 Gy. However, combining a prodrug of RSU1069 with a reduced radiotherapy dose of 10 Gy represents a curative regimen (50% tumour-free survival; day 100) in the HRE-P450R xenografts. In complete contrast, 100% mortality was apparent by day 44 in the empty vector control xenografts treated in the same way. Thus, an oxygen-sensitive gene-directed enzyme prodrug therapy approach may have utility when incorporated into conventional radiotherapy and/or chemotherapy protocols for loco-regional disease in any tissue where hypoxia is a contra-indication to treatment success. doi:10.1038/sj.gt.3301702
CitationOxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. 2002, 9 (14):946-54 Gene Ther.
- A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
- Authors: McErlane V, Yakkundi A, McCarthy HO, Hughes CM, Patterson LH, Hirst DG, Robson T, McKeown SR
- Issue date: 2005 Jul
- Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure.
- Authors: Cowen RL, Williams KJ, Chinje EC, Jaffar M, Sheppard FC, Telfer BA, Wind NS, Stratford IJ
- Issue date: 2004 Feb 15
- Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
- Authors: Jounaidi Y, Waxman DJ
- Issue date: 2000 Jul 15
- Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
- Authors: Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ
- Issue date: 2003 Sep
- Genetically modified macrophages expressing hypoxia regulated cytochrome P450 and P450 reductase for the treatment of cancer.
- Authors: Kan O, Day D, Iqball S, Burke F, Grimshaw MJ, Naylor S, Binley K
- Issue date: 2011 Feb